395 related articles for article (PubMed ID: 24309094)
1. Pseudomonas aeruginosa biofilm: potential therapeutic targets.
Sharma G; Rao S; Bansal A; Dang S; Gupta S; Gabrani R
Biologicals; 2014 Jan; 42(1):1-7. PubMed ID: 24309094
[TBL] [Abstract][Full Text] [Related]
2. Recent perspectives on the molecular basis of biofilm formation by Pseudomonas aeruginosa and approaches for treatment and biofilm dispersal.
Skariyachan S; Sridhar VS; Packirisamy S; Kumargowda ST; Challapilli SB
Folia Microbiol (Praha); 2018 Jul; 63(4):413-432. PubMed ID: 29352409
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.
Tolker-Nielsen T
APMIS Suppl; 2014 Dec; (138):1-51. PubMed ID: 25399808
[TBL] [Abstract][Full Text] [Related]
4. Exopolysaccharide-Repressing Small Molecules with Antibiofilm and Antivirulence Activity against Pseudomonas aeruginosa.
van Tilburg Bernardes E; Charron-Mazenod L; Reading DJ; Reckseidler-Zenteno SL; Lewenza S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223377
[TBL] [Abstract][Full Text] [Related]
5. Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms.
Cole SJ; Records AR; Orr MW; Linden SB; Lee VT
Infect Immun; 2014 May; 82(5):2048-58. PubMed ID: 24595142
[TBL] [Abstract][Full Text] [Related]
6. An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal.
Harmsen M; Yang L; Pamp SJ; Tolker-Nielsen T
FEMS Immunol Med Microbiol; 2010 Aug; 59(3):253-68. PubMed ID: 20497222
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic factors of Pseudomonas aeruginosa - the role of biofilm in pathogenicity and as a target for phage therapy.
Al-Wrafy F; Brzozowska E; Górska S; Gamian A
Postepy Hig Med Dosw (Online); 2017 Feb; 71(0):78-91. PubMed ID: 28258668
[TBL] [Abstract][Full Text] [Related]
8. Molecular Determinants of the Thickened Matrix in a Dual-Species Pseudomonas aeruginosa and Enterococcus faecalis Biofilm.
Lee K; Lee KM; Kim D; Yoon SS
Appl Environ Microbiol; 2017 Nov; 83(21):. PubMed ID: 28842537
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies.
Taylor PK; Yeung AT; Hancock RE
J Biotechnol; 2014 Dec; 191():121-30. PubMed ID: 25240440
[TBL] [Abstract][Full Text] [Related]
10. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis.
Kalishwaralal K; BarathManiKanth S; Pandian SR; Deepak V; Gurunathan S
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):340-4. PubMed ID: 20493674
[TBL] [Abstract][Full Text] [Related]
11. The role of bacterial biofilms in chronic infections.
Bjarnsholt T
APMIS Suppl; 2013 May; (136):1-51. PubMed ID: 23635385
[TBL] [Abstract][Full Text] [Related]
12. Polysaccharides serve as scaffold of biofilms formed by mucoid Pseudomonas aeruginosa.
Yang L; Hengzhuang W; Wu H; Damkiaer S; Jochumsen N; Song Z; Givskov M; Høiby N; Molin S
FEMS Immunol Med Microbiol; 2012 Jul; 65(2):366-76. PubMed ID: 22309122
[TBL] [Abstract][Full Text] [Related]
13. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.
Jakobsen TH; Bjarnsholt T; Jensen PØ; Givskov M; Høiby N
Future Microbiol; 2013 Jul; 8(7):901-21. PubMed ID: 23841636
[TBL] [Abstract][Full Text] [Related]
14. The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms.
Ma L; Wang S; Wang D; Parsek MR; Wozniak DJ
FEMS Immunol Med Microbiol; 2012 Jul; 65(2):377-80. PubMed ID: 22309106
[TBL] [Abstract][Full Text] [Related]
15. Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms.
Baker P; Hill PJ; Snarr BD; Alnabelseya N; Pestrak MJ; Lee MJ; Jennings LK; Tam J; Melnyk RA; Parsek MR; Sheppard DC; Wozniak DJ; Howell PL
Sci Adv; 2016 May; 2(5):e1501632. PubMed ID: 27386527
[TBL] [Abstract][Full Text] [Related]
16. Catheter-related infections caused by Pseudomonas aeruginosa: virulence factors involved and their relationships.
Olejnickova K; Hola V; Ruzicka F
Pathog Dis; 2014 Nov; 72(2):87-94. PubMed ID: 24842562
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy of bacterial and fungal biofilm infections.
Biel MA
Methods Mol Biol; 2010; 635():175-94. PubMed ID: 20552348
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
[TBL] [Abstract][Full Text] [Related]
19. Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of Pseudomonas aeruginosa.
Delissalde F; Amábile-Cuevas CF
Int J Antimicrob Agents; 2004 Oct; 24(4):405-8. PubMed ID: 15380270
[TBL] [Abstract][Full Text] [Related]
20. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae.
Lee MY; Ko KS; Song JH; Peck KR
J Antimicrob Chemother; 2007 Oct; 60(4):782-7. PubMed ID: 17681978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
